Peripheral blood and tumor biomarkers in patients with advanced melanoma treated with combination nivolumab (anti-PD-1, BMS-936558, ONO-4538) and ipilimumab
نویسندگان
چکیده
Peripheral blood and tumor biomarkers in patients with advanced melanoma treated with combination nivolumab (anti-PD-1, BMS-936558, ONO-4538) and ipilimumab Margaret K Callahan, Christine E Horak, Michael A Curran, Travis Hollman, David A Schaer, Jianda Yuan, Alexander M Lesokhin, Shigehisa Kitano, Quan Hong, Charlotte E Ariyan, Klaus J Busam, William Feely, Maria Jure-Kunkel, Joseph Grosso, Jason S Simon, Alan J Korman, Jon M Wigginton, Ashok K Gupta, Xiaoling Zhang, Therese Phillips, Pauline Simmons, Mario Sznol, Jedd D Wolchok
منابع مشابه
melanoma and other skin tumours 1085O SURVIVAL, RESPONSE DURATION, AND ACTIVITY BY BRAF MUTATION (MT) STATUS IN A PHASE 1 TRIALOF NIVOLUMAB (ANTI-PD-1, BMS-936558, ONO-4538) AND IPILIMUMAB (IPI) CONCURRENT THERAPY IN ADVANCEDMELANOMA (MEL)
H. Kluger1, M. Sznol1, M. Callahan2, M. Postow2, R. Gordon2, N.H. Segal2, N. Rizvi2, A. Lesokhin2, M.B. Atkins3, J. Kirkwood4, M. Burke5, A. Ralabate6, A. Rivera6, S. Kronenberg2, B.U. Agunwamba2, W. Feely7, Q. Hong7, S. Krishnan7, J. Wolchok2 Yale Cancer Center, Yale Comprehensive Cancer Center (Smilow Cancer Hospital at Yale-New Haven), New Haven, CT, USA Ludwig Center, Memorial Sloan Ketteri...
متن کاملPeripheral blood clinical laboratory variables associated with outcomes following combination nivolumab and ipilimumab immunotherapy in melanoma
Both the combination of nivolumab + ipilimumab and single-agent anti-PD-1 immunotherapy have demonstrated survival benefit for patients with advanced melanoma. As the combination has a high rate of serious side effects, further analyses in randomized trials of combination versus anti-PD-1 immunotherapy are needed to understand who benefits most from the combination. Clinical laboratory values t...
متن کاملPreclinical Development of Ipilimumab and Nivolumab Combination Immunotherapy: Mouse Tumor Models, In Vitro Functional Studies, and Cynomolgus Macaque Toxicology
The monoclonal antibodies ipilimumab (anti-CTLA-4) and nivolumab (anti-PD-1) have shown remarkable antitumor activity in an increasing number of cancers. When combined, ipilimumab and nivolumab have demonstrated superior activity in patients with metastatic melanoma (CHECKMATE-067). Here we describe the preclinical development strategy that predicted these clinical results. Synergistic antitumo...
متن کاملSuccessful Treatment of Nivolumab-Resistant Multiple In-Transit Melanomas with Ipilimumab and Topical Imiquimod
Simultaneous or sequential, planned administration of ipilimumab could significantly enhance the antitumor effects of nivolumab in advanced melanoma patients. On the other hand, the efficacy of ipilimumab for nivolumab-resistant advanced melanoma is extremely poor. Therefore, additional supportive therapy for anti-PD-1 antibody therapy-resistant advanced melanoma has been widely investigated. I...
متن کاملThe efficacy and safety of nivolumab in previously treated advanced non-small-cell lung cancer: a meta-analysis of prospective clinical trials
BACKGROUND Nivolumab (BMS-936558/ONO-4538) was the first monoclonal antibody targeting programmed death (PD)-1. So far, a number of clinical trials on nivolumab have showed satisfactory efficacy in treating non-small-cell lung cancer (NSCLC). Herein, we present a meta-analysis evaluating the efficacy and safety of nivolumab for previously treated advanced NSCLC patients. METHODS Electronic da...
متن کامل